{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:47Z","timestamp":1792784927214,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"27","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300675"],"award-info":[{"award-number":["82300675"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Research and Development Program of Hubei Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2024,6,28]]},"DOI":"10.1038\/s41388-024-03056-7","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T14:03:13Z","timestamp":1715868193000},"page":"2063-2077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation"],"prefix":"10.1038","volume":"43","author":[{"given":"Xiaomian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangwenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiangen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-3803","authenticated-orcid":false,"given":"Yufeng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"3056_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3056_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3056_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606.","journal-title":"J Hepatol"},{"key":"3056_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J HEPATOL. 2019;70:151\u201371.","journal-title":"J HEPATOL"},{"key":"3056_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3056_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM. Non-alcoholic fatty liver disease\u2013a global public health perspective. J HEPATOL. 2019;70:531\u201344.","journal-title":"J HEPATOL"},{"key":"3056_CR7","unstructured":"Organization, GWH. Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. 2022."},{"key":"3056_CR8","first-page":"456","volume":"18","author":"J Hindson","year":"2021","unstructured":"Hindson J. Molecular landscape of NASH-HCC. Nature Reviews Gastroenterology & Hepatology. 2021;18:456\u2013456.","journal-title":"Hepatology"},{"key":"3056_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/cancers10110447","volume":"10","author":"H Nakagawa","year":"2018","unstructured":"Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, Koike K. Lipid metabolic reprogramming in hepatocellular carcinoma. Cancers. 2018;10:447.","journal-title":"Cancers"},{"key":"3056_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.tem.2023.02.007","volume":"34","author":"K Xu","year":"2023","unstructured":"Xu K, Xia P, Chen X, Ma W, Yuan Y. ncRNA-mediated fatty acid metabolism reprogramming in HCC. Trends Endocrinol Metab. 2023;34:278\u201391.","journal-title":"Trends Endocrinol Metab"},{"key":"3056_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08245-z","volume":"10","author":"L Xiong","year":"2019","unstructured":"Xiong L, Wu F, Wu Q, Xu L, Cheung OK, Kang W, et al. Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming. Nat Commun. 2019;10:335.","journal-title":"Nat Commun"},{"key":"3056_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.molcel.2020.07.012","volume":"79","author":"K Horisawa","year":"2020","unstructured":"Horisawa K, Udono M, Ueno K, Ohkawa Y, Nagasaki M, Sekiya S, et al. The dynamics of transcriptional activation by hepatic reprogramming factors. MOL CELL. 2020;79:660\u2013676.e668.","journal-title":"MOL CELL"},{"key":"3056_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2019-318918","volume":"70","author":"F J\u00fchling","year":"2021","unstructured":"J\u00fchling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, et al. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut. 2021;70:157\u201369.","journal-title":"Gut"},{"key":"3056_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3056_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/hep.31391","volume":"73","author":"Z Hall","year":"2021","unstructured":"Hall Z, Chiarugi D, Charidemou E, Leslie J, Scott E, Pellegrinet L, et al. Lipid remodeling in hepatocyte proliferation and hepatocellular carcinoma. Hepatol (Baltim, Md). 2021;73:1028\u201344.","journal-title":"Hepatol (Baltim, Md)"},{"key":"3056_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116\u201341.","journal-title":"Free Radic Biol Med"},{"key":"3056_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/antiox10020174","volume":"10","author":"JC Arroyave-Ospina","year":"2021","unstructured":"Arroyave-Ospina JC, Wu Z, Geng Y, Moshage H. Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: Implications for prevention and therapy. Antioxidants. 2021;10:174.","journal-title":"Antioxidants"},{"key":"3056_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/antiox11010091","volume":"11","author":"Y Ma","year":"2021","unstructured":"Ma Y, Lee G, Heo S-Y, Roh Y-S. Oxidative stress is a key modulator in the development of nonalcoholic fatty liver disease. Antioxidants. 2021;11:91.","journal-title":"Antioxidants"},{"key":"3056_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12072-020-10121-2","volume":"15","author":"Y Geng","year":"2021","unstructured":"Geng Y, Faber KN, de Meijer VE, Blokzijl H, Moshage H. How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol Int. 2021;15:21\u201335.","journal-title":"Hepatol Int"},{"key":"3056_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","volume":"11","author":"P Rada","year":"2020","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? Cell death Dis. 2020;11:802.","journal-title":"Cell death Dis"},{"key":"3056_CR21","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/cancers12061419","volume":"12","author":"M Sangineto","year":"2020","unstructured":"Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid metabolism in development and progression of hepatocellular carcinoma. Cancers. 2020;12:1419.","journal-title":"Cancers"},{"key":"3056_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.celrep.2015.09.010","volume":"13","author":"H Kim","year":"2015","unstructured":"Kim H, Rodriguez-Navas C, Kollipara RK, Kapur P, Pedrosa I, Brugarolas J, et al. Unsaturated fatty acids stimulate tumor growth through stabilization of \u03b2-catenin. Cell Rep. 2015;13:495\u2013503.","journal-title":"Cell Rep."},{"key":"3056_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/2472555220965528","volume":"26","author":"T Ishida","year":"2021","unstructured":"Ishida T, Ciulli A. E3 ligase ligands for PROTACs: how they were found and how to discover new ones. SLAS Discov: Advancing Sci Drug Discov. 2021;26:484\u2013502.","journal-title":"SLAS Discov: Advancing Sci Drug Discov"},{"key":"3056_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411\u201328.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3056_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","volume":"70","author":"CM Pickart","year":"2001","unstructured":"Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503\u201333.","journal-title":"Annu Rev Biochem"},{"key":"3056_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15578-1","volume":"11","author":"M-K Ge","year":"2020","unstructured":"Ge M-K, Zhang N, Xia L, Zhang C, Dong S-S, Li Z-M, et al. FBXO22 degrades nuclear PTEN to promote tumorigenesis. Nat Commun. 2020;11:1720.","journal-title":"Nat Commun"},{"key":"3056_CR27","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1111\/cas.15883","volume":"114","author":"F Lu","year":"2023","unstructured":"Lu F, Ye M, Hu C, Chen J, Yan L, Gu D, et al. FABP5 regulates lipid metabolism to facilitate pancreatic neuroendocrine neoplasms progression via FASN mediated Wnt\/\u03b2\u2010catenin pathway. Cancer Sci. 2023;114:3553\u201367.","journal-title":"Cancer Sci"},{"key":"3056_CR28","first-page":"2464","volume":"116","author":"M Matsumoto","year":"2006","unstructured":"Matsumoto M, Han S, Kitamura T, Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Investig. 2006;116:2464\u201372.","journal-title":"J Clin Investig"},{"key":"3056_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.plipres.2017.04.002","volume":"66","author":"Y Li","year":"2017","unstructured":"Li Y, Ma Z, Jiang S, Hu W, Li T, Di S, et al. A global perspective on FOXO1 in lipid metabolism and lipid-related diseases. Prog lipid Res. 2017;66:42\u201349.","journal-title":"Prog lipid Res"},{"key":"3056_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3056_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","volume":"77","author":"PA Shah","year":"2023","unstructured":"Shah PA, Patil R, Harrison SA. NAFLD\u2010related hepatocellular carcinoma: The growing challenge. Hepatol (Baltim, Md). 2023;77:323\u201338.","journal-title":"Hepatol (Baltim, Md)"},{"key":"3056_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105218","volume":"161","author":"SW Xia","year":"2020","unstructured":"Xia SW, Wang ZM, Sun SM, Su Y, Li ZH, Shao JJ, et al. Endoplasmic reticulum stress and protein degradation in chronic liver disease. Pharmacol Res. 2020;161:105218.","journal-title":"Pharmacol Res"},{"key":"3056_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114764","volume":"193","author":"JS Park","year":"2021","unstructured":"Park JS, Ma H, Roh YS. Ubiquitin pathways regulate the pathogenesis of chronic liver disease. Biochemical Pharmacol. 2021;193:114764.","journal-title":"Biochemical Pharmacol"},{"key":"3056_CR34","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.15252\/embr.201540891","volume":"16","author":"L Herhaus","year":"2015","unstructured":"Herhaus L, Dikic I. Expanding the ubiquitin code through post-translational modification. EMBO Rep 2015;16:1071\u201383.","journal-title":"EMBO Rep"},{"key":"3056_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.685011","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang F. Post-translational modifications of deubiquitinating enzymes: expanding the ubiquitin code. Front Pharm. 2021;12:685011.","journal-title":"Front Pharm"},{"key":"3056_CR36","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.molcel.2007.11.019","volume":"28","author":"T Hunter","year":"2007","unstructured":"Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell. 2007;28:730\u20138.","journal-title":"Mol Cell"},{"key":"3056_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","volume":"5","author":"L Deng","year":"2020","unstructured":"Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5:11.","journal-title":"Signal Transduct Target Ther"},{"key":"3056_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01262-x","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. MOL Cancer. 2020;19:146.","journal-title":"MOL Cancer"},{"key":"3056_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04620-y","volume":"9","author":"F Yao","year":"2018","unstructured":"Yao F, Zhou Z, Kim J, Hang Q, Xiao Z, Ton BN, et al. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity. NAT COMMUN. 2018;9:2269.","journal-title":"NAT COMMUN"},{"key":"3056_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cell.2006.11.040","volume":"128","author":"LC Trotman","year":"2007","unstructured":"Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128:141\u201356.","journal-title":"Cell"},{"key":"3056_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s42003-020-01367-5","volume":"3","author":"J Seo","year":"2020","unstructured":"Seo J, Jeong DW, Park JW, Lee KW, Fukuda J, Chun YS. Fatty-acid-induced FABP5\/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells. Commun Biol. 2020;3:638.","journal-title":"Commun Biol"},{"key":"3056_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.biopha.2018.06.040","volume":"106","author":"L Pan","year":"2018","unstructured":"Pan L, Xiao H, Liao R, Chen Q, Peng C, Zhang Y, et al. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6\/STAT3\/VEGFA pathway in hepatocellular carcinoma. Biomedicine Pharmacother. 2018;106:68\u201376.","journal-title":"Biomedicine Pharmacother"},{"key":"3056_CR43","doi-asserted-by":"publisher","first-page":"14941","DOI":"10.1074\/jbc.M113.514646","volume":"289","author":"EH Armstrong","year":"2014","unstructured":"Armstrong EH, Goswami D, Griffin PR, Noy N, Ortlund EA. Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor \u03b2\/\u03b4 (FABP5-PPAR\u03b2\/\u03b4) signaling pathway. J Biol Chem. 2014;289:14941\u201354.","journal-title":"J Biol Chem"},{"key":"3056_CR44","first-page":"4770","volume":"73","author":"H Suppresses","year":"2013","unstructured":"Suppresses H. Genetic ablation of the fatty acid. Cancer Res. 2013;73:4770.","journal-title":"Cancer Res"},{"key":"3056_CR45","doi-asserted-by":"crossref","unstructured":"Chen, H, Tan, H, Wan, J, Zeng, Y, Wang, J, Wang, H et al. PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. Pharmacology & therapeutics, 108391 (2023).","DOI":"10.1016\/j.pharmthera.2023.108391"},{"key":"3056_CR46","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","volume":"72","author":"Z Xiong","year":"2023","unstructured":"Xiong Z, Chan SL, Zhou J, Vong JS, Kwong TT, Zeng X, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut. 2023;72:1758\u201373.","journal-title":"Gut"},{"key":"3056_CR47","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwaelder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease\u2013novel insights into cellular communication circuits. J HEPATOL. 2022;77:1136\u201360.","journal-title":"J HEPATOL"},{"key":"3056_CR48","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450\u20136.","journal-title":"Nature"},{"key":"3056_CR49","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1194\/jlr.R066357","volume":"57","author":"P Hirsova","year":"2016","unstructured":"Hirsova P, Ibrabim SH, Gores GJ, Malhi H. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis [S]. J lipid Res. 2016;57:1758\u201370.","journal-title":"J lipid Res"},{"key":"3056_CR50","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","volume":"69","author":"C Lebeaupin","year":"2018","unstructured":"Lebeaupin C, Vall\u00e9e D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J HEPATOL. 2018;69:927\u201347.","journal-title":"J HEPATOL"},{"key":"3056_CR51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s13679-021-00431-3","volume":"10","author":"C-M Flessa","year":"2021","unstructured":"Flessa C-M, Kyrou I, Nasiri-Ansari N, Kaltsas G, Papavassiliou AG, Kassi E, et al. Endoplasmic reticulum stress and autophagy in the pathogenesis of non-alcoholic fatty liver disease (NAFLD): current evidence and perspectives. Curr Obes Rep. 2021;10:134\u201361.","journal-title":"Curr Obes Rep."},{"key":"3056_CR52","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2174\/0929867327666200114114142","volume":"28","author":"M Vincenzi","year":"2021","unstructured":"Vincenzi M, Mercurio FA, Leone M. Protein Interaction domains: structural features and drug discovery applications (Part 2). Curr Med Chem. 2021;28:854\u201392.","journal-title":"Curr Med Chem"},{"key":"3056_CR53","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1039\/C5SC01588J","volume":"6","author":"S Goggins","year":"2015","unstructured":"Goggins S, Marsh BJ, Lubben AT, Frost CG. Signal transduction and amplification through enzyme-triggered ligand release and accelerated catalysis. Chem Sci. 2015;6:4978\u201385.","journal-title":"Chem Sci"},{"key":"3056_CR54","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrd.2016.29","volume":"15","author":"DE Scott","year":"2016","unstructured":"Scott DE, Bayly AR, Abell C, Skidmore J. Small molecules, big targets: drug discovery faces the protein\u2013protein interaction challenge. Nat Rev Drug Discov. 2016;15:533\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"3056_CR55","doi-asserted-by":"publisher","first-page":"14771","DOI":"10.1073\/pnas.0706578104","volume":"104","author":"AD Tward","year":"2007","unstructured":"Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA. 2007;104:14771\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3056_CR56","first-page":"493","volume":"9","author":"SA Stewart","year":"2003","unstructured":"Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (N. Y). 2003;9:493\u2013501.","journal-title":"RNA (N. Y)"},{"key":"3056_CR57","doi-asserted-by":"crossref","unstructured":"Chow S-C, Shao J, Wang H & Lokhnygina Y. Sample size calculations in clinical research. (chapman and hall\/CRC, 2017).","DOI":"10.1201\/9781315183084"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03056-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:02:34Z","timestamp":1719543754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03056-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":57,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024,6,28]]}},"alternative-id":["3056"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03056-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"4 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki principles. All animal experiments were approved by the Animal Use and Care Committees at Zhongnan Hospital, Wuhan University (License No. WP20220494). The human samples and data usage was reviewed and approved by the Scientific Research Ethics Committee of Zhongnan Hospital, Wuhan University (License No. 2022076\u2009K).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}